AM-005

Vistagen's PALISADE Phase 3 program for fasedienol, a novel intranasal treatment for social anxiety disorder, progresses with multiple trials on track for top-line results in 2025.

Vistagen announced positive Phase 2A results for PH284 nasal spray in cancer cachexia, showing improved hunger feelings.

Vistagen has commenced a Phase 2 trial evaluating repeat doses of fasedienol nasal spray for acute treatment of social anxiety disorder (SAD).

VistaGen Therapeutics is progressing with Phase 3 clinical trials for fasedienol, a drug candidate for Social Anxiety Disorder (SAD).

VistaGen's Phase 3 trials for fasedienol in acute social anxiety disorder are progressing, with PALISADE-4 active and results expected from PALISADE-3 and PALISADE-4 in 2025.